

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S.W. Fesik, et al.

Serial No.: 09/716,395

Filed: November 20, 2000

For: MUTANT BCL-2 PROTEINS AND

USES THEREOF

Attorney Docket No.: 6752.US.01

Examiner: B. Brumback

Group Art Unit: 1642

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient

postage as First Class Mail addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231, on:

Date of Deposit:

3-14-03

TECH CENTER 1600/2900

MAR 2 1 2003

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington D.C. 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled MUTANT BCL-2 PROTEINS AND USES THEREOF are the following:

- Information Disclosure Statement (1 Page); 1.
- 2. Form PTO 1449 (1 Page), in duplicate;
- 3. Copy of International Search Report (5 Pages)
- 4. References as cited on Form PTO 1449 (4 References); and
- 5. Return Receipt Postcard

The Commissioner is herby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES

Telephone: (847) 938-3137 Facsimile: (847) 938-2623

Respectfully submitted, Stephen W. Fesik, et al.

Dianne Casuto

Registration No. 40,943

Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appricants: S.W. Fesik, et al.

Serial No.: 09/716,395

Filed: November 20, 2000

For: MUTANT BCL-2 PROTEINS AND

USES THEREOF

Attorney Docket No.: 6752.US.01

Examiner: B. Brumback

Group Art Unit: 1642

Certificate of Mailing under 37 CFR §1.8(a): I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal

Service on the date shown below with sufficient postage as First Class Mail addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231, on:

Date of Deposit:

Mouly

Date

INFORMATION DISCLOSURE STATEMENT

RECEIVED

MAR 2 1 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §1.97 and §1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO 1449 listing the references known to them. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of the references are also enclosed.

Each document listed in this Information Disclosure Statement was first cited by a foreign patent office in a communication from the European Patent Office in a counterpart international PCT application.

This Information Disclosure Statement is submitted after the first Office Action on the merits, but before the issuance of a final action or a notice of allowance. Authorization to charge Deposit Account No. 01-0025 in the amount necessary to cover the cost of this Information Disclosure Statement under 37 C.F.R. 1.17(p) is provided in the Transmittal Letter, submitted herewith.

23492

ABBOTT LABORATORIES Telephone: (847) 938-3137

Facsimile: (847) 938-2623

Dianne Casuto

Registration No. 40,943 Attorney for Applicants

Respectfully submitted, Stephen W. Fesik, et al.